CHO-K1/ADRA1A Stable Cell Line
Recombinant CHO-K1 cells stably overexpress human adrenoceptor alpha 1A (ADRA1A) on the surface and contain high levels of G protein Gαq to couple with the receptor in downstream signaling pathways.
| 询价 | |
| M00225 | |
|
|
|
|
|
|
|
|
|
| 询价 | |
| M00225 | |
|
|
|
|
|
|
|
|
|
| Product Description | Recombinant CHO-K1 cells stably overexpress human adrenoceptor alpha 1A (ADRA1A) on the surface and contain high levels of G protein Gαq to couple with the receptor in downstream signaling pathways. |
| Culture Properties | Adherent. |
| Stability | Stability: Stable through more than 15 passages with no significant changes in assay performance or expression profile. |
| Size | Two vials of frozen cells (>1×106 per vial in 1 mL). |
| Storage | Store cells in liquid nitrogen immediately upon receipt. Thaw and recover cells within one year from the date received. |
| Culture Medium | Ham’s F-12K (Kaighn’s), 10% FBS, 400 μg/ml Geneticin (Cat. No. 10131-035, Life Technologies) |
| Complete Growth Medium | Ham’s F-12K (Kaighn’s), 10% FBS. |
| Freeze Medium-DATA | 45% Ham’s F-12K (Kaighn’s) (Cat. No. 21127, Life Technologies), 45% FBS (Cat. No. 10099-141, Life Technologies), 10% DMSO (Cat. No. D2650, Sigma). |
Figure 1. Epinephrine-induced concentration-dependent stimulation of intracellular calcium mobilization in CHO-K1/ADRA1A cells. The cells were loaded with Calcium-4 prior to being stimulated with agonist Epinephrine. The intracellular calcium change was normalized and measured by FLIPR. The relative fluorescent units (RFU) were normalized and plotted against the log of the cumulative doses of Epinephrine (Mean ± SEM, n = 3). The EC50 of Epinephrine on this cell was 0.72 nM.
Notes:
EC50 value is calculated with four parameter logistic equation:
Y=Bottom + (Top-Bottom) / (1+10^((LogEC50-X)*Hill Slope))
X is the logarithm of concentration. Y is the response
Y is RFU and starts at Bottom and goes to Top with a sigmoid shape. »
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
